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Objectives: Commercially produced sterile green bottle ﬂy Lucilia sericata maggots are successfully employed
by practitioners worldwide to clean a multitude of chronic necrotic wounds and reduce wound bacterial
burdens during maggot debridement therapy (MDT). Secretions from the maggots exhibit antimicrobial activity
along with other activities beneﬁcial for wound healing. With the rise of multidrug-resistant bacteria, new
approaches to identifying the active compounds responsible for the antimicrobial activity within this treatment
are imperative. Therefore, the aim of this study was to use a novel approach to investigate the output of
secreted proteins from the maggots under conditions mimicking clinical treatments.
Methods: cDNA libraries constructed from microdissected salivary glands and whole maggots, respectively,
were treated with transposon-assisted signal trapping (TAST), a technique selecting for the identiﬁcation of
secreted proteins. Several putative secreted components of insect immunity were identiﬁed, including a defen-
sin named lucifensin, which was produced recombinantly as a Trx-fusion protein in Escherichia coli, puriﬁed
using immobilized metal afﬁnity chromatography and reverse-phase HPLC, and tested in vitro against Gram-
positive and Gram-negative bacterial strains.
Results: Lucifensin was active against Staphylococcus carnosus, Streptococcus pyogenes and Streptococcus
pneumoniae (MIC 2 mg/L), as well as Staphylococcus aureus (MIC 16 mg/L). The peptide did not show anti-
microbial activity towards Gram-negative bacteria. The MIC of lucifensin for the methicillin-resistant
S. aureus and glycopeptide-intermediate S. aureus isolates tested ranged from 8 to .128 mg/L.
Conclusions: The TASTresults did not reveal any highly secreted compounds with putative antimicrobial activity,
implying an alternative antimicrobial activity of MDT. Lucifensin showed antimicrobial activities comparable to
other defensins and could have potential as a future drug candidate scaffold, for redesign for other applications
besides the topical treatment of infected wounds.
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Introduction
Maggots of the blowﬂy Lucilia sericata have been successfully
used as a debridement agent for chronic and infected wounds
through history. First used by tribal people, maggot debridement
therapy (MDT) was introduced into Western medicine following
World War I by Baer,
1 and extensively used to treat osteomyelitis
and gas gangrenous wounds. Following the rediscovery of
Alexander Fleming’s penicillin from 1929 by Howard Florey and
colleagues in 1939, the use of surgical maggots was aban-
doned.
2 However, due to the appearance of antibiotic resistance
and increasing problems with chronic wounds worldwide, the
treatment has seen a renaissance in modern medicine through
pioneering work by Church, Sherman
3 and other biotherapy
advocates. The FDA has approved MDT as a medical device,
and maggots are produced aseptically and delivered by commer-
cial companies to wound care centres and hospitals worldwide.
MDT has at least two conﬁrmed beneﬁcial effects when
applied to wounds. These are debridement (removal of necrotic
tissue)
4 and the removal of pathogenic bacteria.
5–7 The
maggots feed through extracorporeal digestion, by excreting a
complex cocktail of enzymes in their excretions/secretions (ES),
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1646mainly trypsin- and chymotrypsin-like proteases,
8 and thereafter
ingesting the resulting liqueﬁed material. It was shown that ES
possess antimicrobial activity in vitro,
9–13 and also break down
bacterial bioﬁlms of Staphylococcus epidermidis,
14 Staphylococcus
aureus and, to a lesser extent, Pseudomonas aeruginosa.
15
However, in vitro studies have questioned the antibacterial
effect of ES on various bacterial species.
16 Recently, we showed
that the mere presence of P. aeruginosa cells is toxic to L. sericata
maggots in an in vivo plate assay via quorum-sensing-regulated
virulence factors.
17
Many studies have aimed at determining the elusive anti-
microbial compounds from maggot ES.
9,10 Low molecular weight
compounds and metabolites have been identiﬁed and tested
in vitro.
18 In a recent expressed sequence tag (EST) project,
septic-inducible genes in L. sericata were investigated, and several
putative peptides and proteins potentially involved in L. sericata
immunity were identiﬁed.
19 Among the septic injury-induced pro-
teins identiﬁed were a sapecin-B homologue, three novel
proline-rich antimicrobial peptides (AMPs), serine proteases and
insect lysozymes. Insect immunity is not only activated as a result
ofphysicalinsult,but also through oralingestionofpathogens.
20,21
Therefore, compounds involved in insect immunity may be active
during MDTas well as the secreted digestive proteins within ES.
In the present study, we use an RNA-based discovery platform,
transposon-assisted signal trapping (TAST),
22 speciﬁcally devel-
oped to identify secreted proteins and peptides. We applied this
to L. sericata maggots induced with external stimuli mimicking
those encountered by the maggots during MDT, without excessive
external insults and from actual MDT treatments, with emphasis
in this study on proteins with putative antimicrobial activity.
Materials and methods
Lucilia sericata maggot inductions
L. sericata maggots were purchased from a commercial supplier (Zoobio-
tic, UK or Biomonde GmBh) and reared aseptically in three groups for
1d a y ( n¼700), 2 days (n¼700) or 3 days (n¼700) at 308C to ﬁrst,
second and third instar levels, respectively, on blood agar medium
[Statens Serum Institut (SSI) art. nr. 677]. In the fourth group, L. sericata
maggots (n¼700) were collected at the Copenhagen Wound Healing
Center at Bispebjerg Hospital following 3 days of successful treatment
of a diabetic patient suffering from large ulcers on both legs. The
maggots were collected through two treatments in succession. The
patient’s ulcers were sampled, and S. aureus and Staphylococcus
warnerii were isolated, but no clinical signs of infection throughout the
collection period were observed.
Seven hundred viable maggots from each of the 1-, 2- and 3-day-old
groups and the MDT-induced group were divided into: (i) a full maggot
(FM) pool (n¼4×100), where whole maggots were ﬂash frozen in liquid
nitrogen and stored at 2808C until further processing; and (ii) a salivary
gland/crop (SC) pool (n¼4×600). The maggots in the SC pool had the
cephalopharyngeal skeleton, salivary glands, crop and proximal part of
the midgut microdissected out in RNA laterTM (Qiagen, Hilden, Germany)
under a stereomicroscope. SC material was stored in RNA laterTM solution
at 2208C until further processing.
RNA extraction
Fenozol reagent (Active Motif, Rixensart, Belgium) was used under RNase-
free conditions to extract total RNA as described by the manufacturer
from the FM pool and the SC pool, separately ground under liquid
nitrogen with a pestle and mortar. The RNA concentration was measured
spectrophotometrically (Ultrospec 3300, Amersham Biosciences) and a
purity of 2.1, as estimated by the OD260/OD280 ratio, was accepted. The
following steps were performed separately for both FM and SC material,
unless otherwise stated.
cDNA library construction
Poly(A) mRNA was extracted from 500 mg of total RNA using the m-trap
total kit (Active Motif, Rixensart, Belgium), according to the manufac-
turer’s instructions. Next, double-stranded cDNA was synthesized
from 0.4 mg of poly(A) mRNA using a SMARTTM PCR cDNA synthesis
kit (Clontech, Mountain View, Canada). First-strand synthesis was
performed using the primer CDS-III/3: 5′-ATTCTAGAGGCCGAGGCGGCC
GAC-ATG-d(T)30 N_1N-3′ in combination with Superscript RT II (Invitrogen,
Carlsbad, USA) reverse transcriptase. Second-strand synthesis was per-
formed using the primer SMART IV: 5′-AAGCAGTGGTATCAACGCAGAGTGG
CCATTACGGC-CGGG-3′ together with Advantage 2TM polymerase (Clon-
tech) using the LD protocol and 20 ampliﬁcation cycles, as described
by the manufacturer.
Double-stranded cDNA was puriﬁed using Illustra GFXTM DNA puriﬁ-
cation spin columns (GFX) (GE Healthcare, Buckinghamshire, UK) and sub-
sequently cut using the restriction enzyme SﬁI (New England Biolabs,
Frankfurt, Germany) for 2 h at 508C in the supplied NE buffer. The
digested cDNA was size separated on a 0.8% agarose gel (Sea Plaque
LMP) to enrich for transcripts of .400 bp. The reconcentrated cDNA frac-
tion .400 bp was excised from the gel and GFX puriﬁed. This was sub-
sequently ligated (168C overnight) into SﬁI cut and GFX puriﬁed signal
trapping vector pMHas7i (kanamycin
r) and as described in international
patent application WO 01/77315
22 using TN4 ligase (New England
Biolabs, Frankfurt, Germany) in the supplied NE buffer. The ligation
mixture was electroporated into Escherichia coli DH10B (Invitrogen) and
then diluted in 1 mL of the supplied SOC medium at 378C (Invitrogen).
Subsequently, bacteria were incubated at 378C for 1 h while shaking at
225 rpm and selected on Luria–Bertani (LB) agar plates supplemented
with 50 mg/mL of kanamycin (378C overnight). Lastly, isolation of
plasmid pool DNA was done for the E. coli colonies (100000 in total)
using the JETSTAR 2.0 midi kit (GENOMED GmbH, Lo ¨hne, Germany),
according to the manufacturer’s instructions.
TAST
TheplasmidusedincloningthecDNAlibrary,pMHas7i,isdescribedininter-
nationalpatentapplicationWO01/77315.Notablefeaturesofthisplasmid
are the SﬁIA–SﬁIB restriction sites proximal to the Shine–Dalgarno region
of the lac promoter. This allows SﬁI-adapted cDNAs to be cloned into the
vector, and the resulting constructs to be actively transcribed and trans-
lated in the E. coli host. The signal-trapping transposon TnSig is also
described in international patent application WO 01/77315. Brieﬂy, the
transposon is a derivative of the MuA mini transposon Entranceposon
(Finnzymes, Oy). Directly adjacent to the left transposon border, an open
reading frame (ORF) of the E. coli b-lactamase gene product, lacking a
signal peptide, is inserted. Insertion of the transposon in a secreted gene
can result in an in-frame fusion, secretion of the b-lactamase fusion
peptide and, consequently, ampicillin-resistant E. coli colonies. The trans-
poson also contains a chloramphenicol resistance gene, so the resulting
DH10B E. coli cells containing a plasmid with a cDNA sequence with a
transposon inserted in-frame with the signal peptide will be kanamycin
r/
ampicillin
r/chloramphenicol
r; designated ‘trappants’.
Thetransposontaggingreactionwascarriedoutbymixing80 ngofpur-
iﬁedTnSigtransposon,
221 mgofplasmidcDNAlibraryand1 mLofHyperMuA
transposase (Epicentre Madison, USA) in 1×Hyper MuA buffer in a reaction
volume of 20 mL. The reaction was incubated at 308Cf o r3h ,a n ds u b -
sequently inactivated by the addition of 1 mL of Hyper MuA stop reagent
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JACandincubationat758Cfor10 min.Thereactionmixturewasethanol/sodium
acetate precipitated, washed twice in 70% ethanol to remove excess salt
andresuspendedin10 mLofTEbuffer, pH8.An aliquot of 2 mLoftheresult-
ing suspension was transformed into DH10B electrocompetent E. coli cells.
The reaction mixture was diluted in 1 mL of SOC medium pre-heated to
378C and incubated at 378C at 225 rpm for 1 h. Three aliquots of 20 mL
were plated onto LB kanamycin, LB kanamycin/chloramphenicol and LB
kanamycin/chloramphenicol/ampicillin for controls, while the rest of the
1 mL was plated on triple antibiotic LB plates with the following antibiotic
concentrations: 50 mg/L kanamycin; 10 mg/L chloramphenicol; and
15 mg/L ampicillin. Plates were incubated for 2 days at 308C and then
1200 colonies were reisolated on new triple antibiotic LB plates (kanamy-
cin/chloramphenicol/ampicillin) to ensure the isolation of surviving, actively
growing‘trappants’.Afteradditionalincubation(24–48 h,308C),1000‘trap-
pants’ from both the FM and SC library were inoculated into 96-well growth
blockswith1 mLofterriﬁcbroth(TB)
23containingkanamycin(50 mg/L)and
chloramphenicol (10 mg/L), and incubated under humid conditions (378C,
2 days).‘Trappant’culturebrothwassupplementedtoatotalconcentration
of 15% glycerol and stored at 2208Cu n t i ls h i p m e n t .
Sequencing
Glycerol stock of 1000 conﬁrmed ‘trappants’ from each library was
shipped to GATC biotech (Konstanz, Germany), and the plasmid inserts
were sequenced with the transposon-anchored TnSig-speciﬁc primers
seqA (5′-AGCGTTTGCGGCCGCGATCC-3′) and seqB (5′-TTATTCGGTCGAAA
AGGATCC-3′).
Bioinformatics analysis
The removal of the vector sequence, trimming of the low quality
sequence and assembly were done with phredPhrap package (http://
www.phrap.org), as described by Becker et al.
22 The resulting contigs
were annotated using the PEDANT genome database,
24,25 manually
inspected using the VnTi software (Invitrogen), and searched against
public and commercial databases. Sequences with putative antimicrobial
activity are listed in Table 1.
Cloning and recombinant expression of L. sericata AMP
ZY200177 (lucifensin)
TheZY200177codingsequencewasampliﬁedfromcDNAusingtheExtensor
high-ﬁdelity PCR system (AB Gene, Surrey, UK) and ZY200177-speciﬁc oligo-
nucleotide primers ZY200177-1: 5′-CCCCCCGGTACCGACGACGACGACA
AGGCTACTTGCGATTTATTGAGTGGTAC-3′ and ZY200177-2: 5′-CCCCCCGAATTC
TTATTAATTACGACACACGCAAATAGC-3′.The165 bpPCRproductwasdigested
ﬁrstwithKpnIinNEbufferIwithBSAadded,GFXpuriﬁedovernightandthen
EcoRIdigested(NewEngland Biolabs) inthesuppliedNEbuffer, whichcutin
the overhangs introduced by the PCR primers.
The digested DNA fragment was ligated into the E. coli expression
plasmid pET32a(+) (Novagen), in an expression approach similar to
that used by Xu and colleagues for recombinant Musca domestica
cecropin.
26,27 The resulting plasmid (pANAS03) encoded a translational
fusion peptide containing an N-terminal thioredoxin part followed by a
his-tag, an enterokinase (EK) cleavage site and, lastly, the mature
peptide sequence of the ZY200177, and was transformed into DH10B
E. coli and the plasmid, with correctly inserted sequence veriﬁed
by sequencing. GFX puriﬁed (pANAS03) from a veriﬁed clone was
transformed into the E. coli strain BL21 (DE3) Singles competent cells
[F–ompT hsdSB(rB
2 mB
2) gal dcm lacY1] (Novagen), as prescribed by
the manufacturer. Ten transformants were reisolated under selective
and non-inducing conditions on LB agar with ampicillin (100 mg/L).
Totesttheexpressionofthe21.18 kDaTrx–lucifensinfusionprotein,10
transformantsweregrownin100 mLofTBsupplementedwith1%glucose
and ampicillin (100 mg/L), at 378C and 200 rpm in 300 mL shakeﬂasks to
an OD600 of  5–10. Shakeﬂasks were subsequently transferred to 158C
for 1 h at 270 rpm. Then, 0.5 mL of each culture was sampled as an unin-
ducedcontrol,andtheculturesweresubsequentlyinducedbyaddingIPTG
to 0.5 mMand incubatedat158C,270 rpmovernight.Next,0.5 mLof each
culture was drawn as induced samples. Cells were pelleted by centrifu-
gation at 10000 g for 5 min and the supernatant removed. The cells
were resuspended in 150 mL of Bugbuster (Novagen) and lysed for
25 min while shaking at 600 rpm at room temperature. The samples
were centrifuged at 10000 g for 5 min and the volume of the supernatant
adjustedfordifferencesinOD600betweensamplingpointsandcheckedon
an SDS gel. Samples were denatured at 958C for 5 min in 1×Novex Tris–
glycine SDS sample buffer with NuPAGE sample reducing agent added.
Pre-cast NuPAGE Novex Bis-Tris mini gels were run on the XCell Sure Lock
Mini Cell System in 1×NuPAGE MES SDS running buffer, with 500 mLo f
NuPAGE antioxidant added to the inner buffer chamber, at 200 V for
30 min. All NuPAGE articles are from Invitrogen (Carlsbad, USA). Gels
were stained for 1 h in InstantBlue (Expedeon, Cambridge, UK) and
destained in sterile milli-Q water overnight. A highly expressing clone was
selected, and a single colony plated and grown in 4 L of TB as described
for initial inductions; culture broth was pelleted by centrifugation and
stored at 2208C until further processing.
Immobilized metal afﬁnity chromatography (IMAC)
Pelleted cells were lysed by suspension in one-quarter of the
cell culture volume in a buffer containing 50 mM Tris–HCl, pH 7.5,
0.04% lysozyme (Sigma), 0.01% benzonase (Sigma), 1% 3-(N,N-
dimethylmyristylammonio)propanesulphonate (SB3-14) (Sigma) and 0.1%
3-(4-heptyl)phenyl-3-hydroxypropyl)dimethylammoniopropanesulphonate
(C7BzO) (Sigma) for 45 min at room temperature. The resulting lysate was
ﬁltered through a 0.22 mm ﬁlter (Nalgene super Mach).
The Trx–lucifensin fusion protein was captured from the soluble frac-
tion using IMAC on an A ¨kta Explorer ﬁtted with a 25 mL TALON column
(GE Healthcare) calibrated with 50 mM Tris–HCl, pH 7.5/1 M urea. The
lysate was added to the column and subsequently washed with
50 mM Tris–HCl, pH 7.5/1 M urea and eluted in a buffer containing
50 mM Tris–HCl, pH 7.5, 500 mM imidazole and 1 M urea. Fractions con-
taining the 21.2 kDa fusion protein were pooled in a Spectra/Por
w dialysis
tube (Spectrum Labs) and dialysed against 50 mM Tris–HCl, pH 7.0/5 mM
CaCl2 at 48C overnight.
EK digestion and reverse-phase chromatography
(RP-HPLC)
To release ZY200177 (hereafter named lucifensin) from the Trx-fusion
protein, EK (Novozymes) (1:75, v/v) was added and the suspension
was incubated at 308C overnight at 200 rpm. The digest was adjusted
with formic acid and loaded onto a Gemini 10 m C18 100 A ˚
250×10 mm column (GE Healthcare) calibrated with 1% formic acid.
The bound protein was subsequently eluted with a linear gradient of
ethanol (0%–80%, v/v). The fractions containing the 4.1 kDa lucifensin
were identiﬁed by SDS gel and antimicrobial activity was veriﬁed in
radial diffusion assays (RDAs) with Staphylococcus carnosus. The fractions
containing lucifensin were pooled and lyophilized in a Genevac EZ-2
solvent evaporation system (Genevac) and resuspended in 0.1% acetic
acid. The purity of lucifensin was estimated to .95% by the appearance
of a single band on an SDS gel. The concentration of the suspended pur-
iﬁed lucifensin was determined using RP-HPLC, where the peptide is
quantiﬁed based on known peptide standards corrected for the extension
coefﬁcient of lucifensin (calculated molar absorbance lucifensin E280
0.398 mg/mL). The lucifensin peptide was puriﬁed to homogeneity
using two consecutive rounds of RP-HPLC.
The monoisotopic molecular mass was determined by UPLC-MS using
a Q-TOF Premier (Waters) connected to an Acquity UPLC (Waters). The
Andersen et al.
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for lock mass. The separation was done on an Acquity BEH300 C4 column
(2.1×150 mm; 1.7 mm; 300 A ˚) using a water-acetonitrile gradient (0.1%
TFA).
RDAs and MIC determination
Initially, the antimicrobial activity of the fractions containing lucifensin was
conﬁrmed using an RDA described previously by Lehrer et al.,
28 with several
modiﬁcations. Brieﬂy, 30 mLof melted 1/10 Mueller–Hinton broth (MHB)
23/
1% agarose was cooled to 428C, supplemented to 5.0×10
5 cfu/mL with
S. carnosus ATCC 51365 and was poured into a single-well omnitray
(Nunc). The omnitray was overlayed with a TSP plate (Nunc) and left to soli-
dify.After 1 h,theTSPplatewasremoved,leaving961-mmwellsinwhich
10 mLof the fractions of interest could be tested. Depending on the solvent
involved, fractions were supplemented with 1 M Tris–HCl, pH 7.5 (1:1, v/v)
prior to analysis in order to neutralize the antimicrobial activity of the
solvent.For the Candida utilis RDA, a similar set-up was usedwiththe modi-
ﬁcation that 1/3 potato dextrose (PD) agarose was used. S. carnosus and C.
utiliswerechosenasreporterstrainsduetotheirhighsusceptibilitytowards
AMPs in the RDA assays.
The strain collection listed in Table 2 was tested for susceptibility to
lucifensin by determining the strain MICs using a microbroth dilution
assay.
29 Colonies of the respective microorganism from a 5% blood
agar plate (SSI) incubated overnight were suspended in MHB, pH 7.4
and diluted in MHB to a concentration of 5.0×10
5 cfu/mL. An aliquot of
90 mL of the bacterial suspension was incubated with 10 mL of lucifensin
or vancomycin, gentamicin, ampicillin, ceftriaxone and linezolid as refer-
ence antibiotics in differing concentrations in polypropylene 96-well
plates (Nunc) for 18–24 h at 378C. The lucifensin peptide and reference
antibiotics solutions were made fresh on the day of the assay and
diluted 2-fold. The concentrations assayed ranged from 0.125 to
128 mg/L and the MIC was recorded as the lowest peptide concentration
at which visual growth was inhibited.
Results
Identiﬁcation of putative antimicrobial proteins
using TAST
The TAST technique employs insertionally mutagenizing a cDNA
library of interest with a transposon containing a b-lactamase
gene without a signal peptide, which therefore encodes an
inactive protein since it is not secreted. Subsequent clones con-
taining a cDNA fragment with the transposon inserted in-frame
to a signal peptide from a secreted protein will confer ampicillin
resistance through secretion of the b-lactamase and allow
clones containing cDNA from a secreted protein to be selected
and the inserted cDNA sequenced.
22 The bioinformatic analysis
of the TAST results from the SC and FM L. sericata libraries
revealed many novel L. sericata secreted proteins, mainly
trypsin- and chymotrypsin-like proteases, lipases and odorant-
binding proteins (results not shown). More interestingly, several
sequences of putative proteins with predicted antimicrobial
activity or with putative functions in insect immunity and, there-
fore, with a possible role in the antimicrobial effect of MDT were
identiﬁed (Table 1). One partial lysozyme 2 and two full-length
lysozyme 1 sequences were identiﬁed. Both lysozyme 1 homol-
ogues ZY200358 and ZY200249 were trapped exclusively from
the SC library, indicating that they may be secreted during
MDT. A partial (ZY200118) and a full-length (ZY200235)
sequence of the L. sericata lectin a-subunit were identiﬁed.
Lectins have been shown to be induced from the fat body in
response to injury in Sarcophaga peregrina.
30 One full-length
sequence (ZY200117) represented a sarcotoxin IIA homologue
belonging to the attacin family. These large proteins are similarly
expressed upon injury
31 and were only recovered from one FM
clone. Among the TAST hits we also identiﬁed the full-length
276 bp ORF ZY200177 with high homology to known insect
defensins with six conserved cysteine residues (Figure 1a). This
comprised a novel L. sericata defensin, which we initially
named sericasin. Based on recent successes with the develop-
ment of defensins for medical applications
32,33 and the overall
potential of this molecule group, the encoded peptide was
recombinantly expressed and puriﬁed for activity testing.
During the revision of this manuscript a study by Cerovsky
et al.
34 was published in which they had successfully identiﬁed
the same peptide from L. sericata ES, gut, salivary glands, fat
body and haemolymph, which they named lucifensin; we
adopted this name for the peptide.
The putative 92 amino acid protein sequence comprised a
signal peptide (amino acids 1–23) predicted by SignalP v. 3.0
(http://www.cbs.dtu.dk/services/SignalP/), a propeptide (amino
Table 1. TAST hits with putative antimicrobial activity or involvement in insect immunity
Accession - BankIt1355267 BlastP UniProt Bit score Amino acid identity Best hit putative function Sequence Clones recovered
ZY200177_HM243535 1.9E-40 168 77/94 (82%) defensin full length 1 FM
ZY200113_HM243536 6.9E-97 358 173/258 (68%) cuticle protein full length 1 FM
ZY200117_HM243534 2,80E-73 279 149/300 (50%) attacin full length 1 FM
ZY200244_HM243537 4,50E-19 97 46/84 (54%) chitin binding protein partial 1 SC
ZY200249_HM243538 2,30E-74 280 129/141 (91%) lysozyme 1 full length 1 SC
ZY200358_HM243539 3,40E-51 204 93/142 (65%) lysozyme 1 full length 3 SC
ZY200466_HM243544 2,90E-32 140 62/70 (89%) lysine-rich lysozyme 2 partial 1 FM
ZY200108_HM243545 2,30E-13 78 48/171 (28%) lectin (alpha subunit) partial 1 FM
ZY200235_HM243540 5,20E-81 304 135/272 (50%) lectin alpha subunit full length 1 SC
ZY200304_HM243546 2,70E-51 205 97/123 (79%) ferritin heavy chain-like partial 1 SC 2 FM
ZY200341_HM243541 3,30E-92 342 166/205 (81%) ferritin heavy chain-like full length 1 SC 3 FM
ZY200373_HM243542 7,90E-96 354 177/225 (79%) ferritin light chain like full length 2 SC 2 FM
ZY200234_HM243543 2,10E-81 308 146/185 (78%) peptidoglycan recognition protein full length 1 SC
Antimicrobial activity of maggot debridement therapy
1649
JACacids 24–52) with a Kex2 cleavage site (amino acids 51–52) and
a mature peptide named lucifensin (amino acids 53–92)
(Figure 1b). Lucifensin was identiﬁed from the FM library and
recovered from 1 clone out of 2000 sequenced containing the
entire ORF. If the peptide was very active during MDT, we
would have expected it to be recovered in high numbers from
both the FM and SC libraries.
Expression and puriﬁcation of Trx–lucifensin fusion
The plasmid pANAS03 containing the Trx–lucifensin fusion was
transformed into E. coli BL21 cells. Upon IPTG induction, lucifensin
was expressed as a fusion protein to thioredoxin (Figure 2). The
soluble fraction of lysed cells harbouring the recombinant
plasmid was analysed by SDS–PAGE (Figure 2a) for the expression
ofthefusionprotein.Aproteinwith anapparentmolecularweight
of 22 kDa was expressed upon induction with IPTG, which is close
to the calculated molecular weight of 21.8 kDa for the fusion
protein. Using IMAC, the fusion protein was captured (Figure 2b).
In order to generate mature lucifensin, the puriﬁed fusion
protein was treated with EK at 308C overnight at 200 rpm
(Figure 2b). Subsequently, the lucifensin peptide was puriﬁed to
homogeneity using two consecutive rounds of RP-HPLC in a
formic acid/ethanol gradient. The second RP-HPLC run removed
additional impurities (Figure 2c) and the antimicrobial activity
of the fractions containing lucifensin assayed by S. carnosus
RDA showed consistency with SDS–PAGE gel band intensities of
the  4 kDa peptide (Figure 2d).
The concentration of recombinant lucifensin was determined
via RP-HPLC and the monoisotopic molecular mass was conﬁrmed
by electrospray Q-TOF MS/MS to be 4113.8783 Da, in agreement
with the calculated mass of 4113.89 Da (results not shown).
Approximately 4 mg of puriﬁed recombinant lucifensin (.95%
purity as judged by SDS gel, Figure 2c) was produced from
IPTG-induced cells pertaining from 1 L of TB culture medium.
Antimicrobial activity of lucifensin
The antimicrobial activity of recombinant lucifensin was tested
against both Gram-negative and Gram-positive bacteria
(Table 2) using a CLSI (formerly NCCLS) MIC assay in which the
reference antibiotics included were within the limits of accep-
tance, thereby complying with CLSI guidelines.
35–37 Lucifensin
was active against S. carnosus, Streptococcus pyogenes and
Streptococcus pneumoniae with MIC values of 2 mg/L, and
against Enterococcus faecalis and S. aureus with MIC values of
32 and 16 mg/L, respectively, but did not show any antimicrobial
activity towards the Gram-negative bacteria tested at concen-
trations ,128 mg/L. Subsequently, to evaluate the activity
of the peptide against S. aureus, MIC assays were performed
for a selection of 15 methicillin-resistant S. aureus (MRSA) and
glycopeptide-intermediate S. aureus (GISA) isolates, including
the predominant European and American clones. The MIC
values for lucifensin against the MRSA and GISA isolates tested
ranged from 8 to .128 mg/L (results not shown). The peptide
did not show antifungal activity, as tested in a RDA with
Consensus
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Figure 1. (a) ClustalWalignment of mature processed insect defensins from: 1, Phormia teranova P10891 (PDB:1ica); 2, TAST-identiﬁed Lucilia sericata
ZY200177-lucifensin; 3, Sarcophaga peregrina P31530; 4, S. peregrina P18313 (PDB:1L4V); and 5, Musca domestica A21900. Boxes in the sequences
indicate amino acid differences compared with lucifensin and the coloured bars indicate the level of overall homology. (b) Schematic
representation of the full-length translation of the ZY200177 ORF containing the putative signal peptide (predicted by SignalP 3.0 Server), the
deduced propeptide with a Kex2 cleavage site and the mature lucifensin defensin with disulphide bridges inferred by homology.
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cannot be ruled out.
Discussion
The emergence of antibiotic resistance in a number of bacterial
species and the alarmingly few new antibiotics being developed
through to the clinic
38 has turned research towards alternative
modes of antimicrobial therapy and the development of novel
antimicrobials.
32 Maggots of L. sericata have been used to treat
infected wounds for centuries and are used currently when
other treatments fail. Therefore, it is apparent to try to identify
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Figure 2. (a) SDS–PAGE analysis of the soluble fraction of the Trx–lucifensin fusion protein in BL21 cells. Lane 2, uninduced; and lane 3, IPTG induced.
(b) SDS–PAGE analysis. Lane 3, IMAC-captured Trx–lucifensin fusion protein; lane 4, enterokinase digest showing  4 kDa released recombinant
lucifensin; and lanes 6–8, ﬁrst round of RP-HPLC fractions containing mature lucifensin. (c) SDS–PAGE analysis of second RP-HPLC puriﬁcation.
Lanes 2–4, fractions containing mature lucifensin (.95% pure). (d) RDAs on S. carnosus of pooled fractions containing lucifensin from the ﬁrst
RP-HPLC (input RPC) and corresponding to (c), lanes 2–4. All samples were adjusted with Tris, pH 7.5, to abrogate the antimicrobial effect of the
solvent formic acid/ethanol.
Table 2. MIC values of lucifensin
Species ATCC no. Lucifensin MIC (mg/L)
Streptococcus pneumoniae 49619 2
Streptococcus pyogenes 12344 2
Staphylococcus carnosus 51365 2
Staphylococcus aureus 29737 8
Staphylococcus epidermidis 12228 32
Enterococcus faecalis 29212 32
Escherichia coli 25922 .128
Pseudomonas aeruginosa 9027 .128
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ponents that could be used in modern medicine.
Previous studies into the antimicrobial activity involved in MDT
have mainly been performed using chromatography-based
approaches, applied to ES of uninjured maggots where substances
with low molecular weight (,500 Da) were identiﬁed.
9 A similar
approach was performed using HPLC to investigate whole maggot
extracts of immune-challenged maggots, and identiﬁed three
known low molecular weight components: p-hydroxybenzoic acid;
p-hydroxyphenylacetic acid; and octahydro-dipyrrolo[1,2-a;1′,2′-d]
pyrazine-5,10-dione, also known as the cyclic dimer of proline or
proline diketopiperazine or cyclo[Pro,Pro].
18 A recent EST project
focused selectively on septically inducible genes in L. sericata
using the subtracted cDNA library approach identiﬁed several
putative peptides and proteins potentially involved in L. sericata
immunity.
19 Among the septic injury induced proteins, a sapecin-B
homologue, a diptericinhomologue, novel proline-rich AMPs, serine
proteases, transferrin, ferritin and insect lysozymes were identiﬁed,
but noneof the identiﬁed partial-lengthsequences were translated
into recombinantly expressed antimicrobial compounds. However,
in parallel to our study, the amino acid sequence of the mature
lucifensin peptide was identiﬁed. The peptide was detected in
trace amounts from L. sericata, ES, gut, salivary glands, fat
body and haemolymph, and the sequence of the mature
peptide was deduced by Edman degradation and shown to have
antimicrobial activity against Micrococcus luteus.
34 These results
thus conﬁrmed the sequence identity of the lucifensin peptide
identiﬁed by the TAST technology.
In this study, we utilized a proprietary mRNA-based discovery
platform (TAST) designed to selectively identify secreted proteins
containing a signal peptide.
22 The method has previously been
used to successfully identify potent AMPs.
32 The method has
the clear advantage that the amount of maggots needed is
limited compared with the amounts used when applying a
strict HPLC approach to purify compounds of interest either
from ES or whole maggot extracts. Compared with other EST
approaches, TAST has the distinct beneﬁt that it selects for
secreted peptides and proteins. As the beneﬁcial activities of
the maggots in MDT are derived from compounds secreted into
the wound environment either in secretions or excretions, this
is ideal. We constructed cDNA libraries from whole maggots
and maggot SCs induced under conditions mimicking the con-
ditions and challenges that the maggots are faced with during
MDT. Furthermore, different instar levels were represented, as
they are present also during the time course of MDT. Sterility of
the maggots in relation to the RNA isolation was not essential,
as the ratio of L. sericata to bacterial RNA was such that any
bacterial sequences trapped could easily be removed in the
bioinformatics and annotation analysis.
One thousand clones containing a signal-trapped gene
from each library were sequenced, and as only 12 clones from
the FM library and 10 clones from the SC library contained
sequences with homology to insect immunity-associated antimi-
crobial proteins, these sequences can with some degree of cer-
tainty be ruled out as antimicrobial effector molecules in MDT,
as they are most likely not highly expressed during MDT. The
number of times that a sequence was ‘trapped’ in individual
clones is an estimate of the actual expression and should be con-
ﬁrmed in future studies of clinical samples. The sequences
reported here can be used as scaffolds for real-time PCR
studies of the actual expression in different L. sericata tissues.
The list of putative secreted proteins identiﬁed during this
study comprises a number of full-length sequences homologous
to proteins involved in immunity in Diptera
39 and other insect
orders.
Insects use an innate immune system to fend off infection,
and innate immunity relies on the detection and recognition of
common microbial components, such as lipopolysaccharides
or peptidoglycans, in order to mount a suitable systemic
response.
40 Lectins and peptidoglycan-recognition proteins
(PGRPs) are important mediators in insect immunity. Their func-
tions include the detection and neutralization of pathogenic and
non-self material, and have been identiﬁed in many insect
species.
41–43 The C-type lectin CLEM-36 has been shown to be
speciﬁcally expressed in the tip of the mouthparts in adult
Sarcophaga peregrina.
44 Flies are exposed to invasion and
colonization of their mouthparts and crop during feeding, from
potentially pathogenic bacteria. The presence of PGRPs is a
perfect defence mechanism in order to avoid colonization in
adult ﬂies and maggots, especially for L. sericata maggots
taking into account their natural habitat in decomposing
cadavers or when used for MDT. We identiﬁed a novel putative
full-length PGRP (ZY200234) and a putative full-length lectin
a-subunit homologue (ZY200235). Both proteins were identiﬁed
from the SC library indicating functions as reported in
S. peregrina; additionally, a partial lectin sequence (ZY200108),
not identical to ZY200235, was also identiﬁed in the FM library.
Furthermore, a full-length and a partial lysozyme 1 homo-
logue were retrieved exclusively from the SC library, indicating
that lysozyme could be present in the secretions of the
maggots and play a part in the antimicrobial activity during
MDT. A partial lysine-rich lysozyme 2 sequence was identiﬁed
from the FMs, similar to an enzyme identiﬁed from whole
immune-induced maggots.
19 However, the sequences were
not identical. The sequence variation of lysozyme secreted by
L. sericata should be further investigated in relation to AMP
activity in MDT.
A large AMP precursor belonging to the attacin family with
homology to sarcotoxin IIA was identiﬁed in the FM library.
Sarcotoxin IIA has been reported to inhibit cell wall synthesis
and septum formation in E. coli,
45 and attacins in general are
active against Gram-negative bacteria. The rather large size of
the attacin polypeptides has rendered activity studies difﬁcult
and, for this reason, limited information is available.
31
The sequence ZY200177 showed high homology to known
insect defensins, including sapecin.
46 Furthermore, using fold rec-
ognition and homology modeling, the peptide was predicted to
adapt to the conserved cysteine-stabilized a-helix and b-sheet
(CSab) structural fold characteristic of peptides belonging to
members of the defensin family. We, thus, decided to recombi-
nantly produce the encoded lucifensin peptide. The activity of
lucifensin was seen to be speciﬁc against Gram-positive micro-
organisms and, most notably, against S. carnosus, S. pneumoniae
and S. pyogenes. MDT has been reported to be effective in eradi-
cating MRSA,
47 and as MRSAs are an expanding problem within
the healthcare sector worldwide and speciﬁcally in the treat-
ment of chronic wounds, the peptide was tested against
several MRSA and GISA isolates. Notably, lucifensin did show
antimicrobial effect against both MRSA and GISA isolates, com-
parable to that reported for other defensins.
33
Andersen et al.
1652An interesting question is whether the lucifensin peptide holds
the potential to be developed into a pharmaceutical drug candi-
date itself or whether its beneﬁt will remain restricted to the
direct application of maggots in wounds only. In general, the
development of AMPs into therapeutics has been hampered by
their potential for toxic side effects, suboptimal efﬁcacy, salt sen-
sitivity, liability to serum proteases, and, most notably, the lack
of cost-effective and commercially viable production systems.
48
However, recent attempts in the development of defensins for
medical applications successfully addressed these issues.
32,33
In combination with the potent activity of lucifensin against clini-
cally relevant Streptococcus species at physiological salt levels, it
appears that the peptide is a promising anti-infective candidate
for further drug development.
Our TAST results did not contain any obvious protein candi-
date sequences with antimicrobial homology that were differen-
tially recovered from the SC library, so the present study cannot
be used to pinpoint lucifensin as the elusive antimicrobial mol-
ecule of MDT. This is in contrast to the parallel work by Cerovsky
et al.,
34 in which they were able to isolate lucifensin from salivary
glands, fat body, ES and haemolymph, indicating that the
peptide could be constitutively expressed as part of the systemic
immune mechanism of L. sericata. In their study, all material
was derived from mid-third instar 4-day-old maggots reared
under non-sterile conditions, so the bacterial challenge leading
to the output of lucifensin was most likely through oral chal-
lenge. These conditions are comparable to our inductions,
though only 50% of the material used in our study was from
3-day-old third instar maggots. If the expression of lucifensin is
late onset, perhaps in preparation for pupation, this may
explain the discrepancy between the studies. The actual
amount of the lucifensin that Cerovsky et al.
34 were able to
recover was not reported, only that they could identify its pres-
ence via antimicrobial activity against the reporter strain
M. luteus. Extrapolating from these results into what the local
concentration of lucifensin in the wound ﬂuid and tissue could
be during MDT is therefore difﬁcult. In the EST project performed
by Altincicek et al.,
19 in which they looked at septic
injury-inducible genes in L. sericata second instar maggots, a
number of AMPs were identiﬁed; however, lucifensin was not
among these. This would support the theory that a time-
dependent expression of the peptide may occur during the
maggot life cycle and, therefore, also during MDT. The Altincicek
et al.
19 study was, like ours, based on a transcriptomics approach
in which the cDNA of the peptides was harboured on plasmids
in E. coli. Although lucifensin does not show antimicrobial
activity against E. coli, counterselection against AMP sequence-
containing clones in E. coli during propagation of the cDNA
library cannot be ruled out. In order to deﬁnitively evaluate
whether lucifensin is indeed the elusive antimicrobial activity
within ES, future studies should validate the expression of luci-
fensin via Q-PCR at different timepoints in the maggot life
cycle. From the present study we cannot establish the nature
of the elusive antimicrobial effect of MDT, but can, however,
report a number of novel full-length components of L. sericata
immunity among which we recombinantly expressed, puriﬁed
and tested lucifensin. Recombinant lucifensin could have poten-
tial as a future drug candidate scaffold, for redesign for other
applications besides the topical treatment of infected wounds,
as has been established for other defensins.
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